Literature DB >> 23457857

The prevalence, clinical features, risk factors and outcome associated with cryptococcal meningitis in HIV positive patients in Kenya.

R Mdodo1, K Brown, E Omonge, W Jaoko, J Baddley, P Pappas, M Colette Kempf, I Aban, S Odera, A Suleh, P E Jolly.   

Abstract

OBJECTIVES: To determine the prevalence, clinical features, risk factors and outcomes associated with cryptococcal meningitis (CM) in human immunodeficiency virus (HIV) positive patients at two referral hospitals in Nairobi, Kenya.
DESIGN: Prospective, observational study.
SETTING: Kenyatta National Hospital (KNH) and Mbagathi District Hospital (MDH), Nairobi, Kenya.
SUBJECTS: Three hundred and forty HIV patients presenting with suspected CM.
RESULTS: Of three hundred and forty suspected CM patients, 111 (33%) were diagnosed with CM by CrAg. Among CM patients, in-hospital mortality was 36% (38/106), median age was 35 years (range, 19-60 years) and median CD4 count was 41 cells/microL (n = 89, range 2-720 cells/microL). Common clinical manifestations among CM patients included headache 103 (93%), neck stiffness 76 (69%) and weight loss 53 (48%). Factors independently associated with CM were male sex, headache, blurred vision and previous antifungal drug use. Night sweats and current use of anti-retroviral therapy were associated with reduced risk for CM.
CONCLUSIONS: There is a high prevalence of CM and CM-associated mortality in HIV patients at KNH and MDH despite treatment with antifungal and anti-retroviral drugs. This study demonstrates the need to address the existing inadequacies of CM patient outcomes in Kenya.

Entities:  

Mesh:

Year:  2010        PMID: 23457857      PMCID: PMC3602928     

Source DB:  PubMed          Journal:  East Afr Med J        ISSN: 0012-835X


  17 in total

1.  Impact of HIV infection on meningitis in Harare, Zimbabwe: a prospective study of 406 predominantly adult patients.

Authors:  J G Hakim; I T Gangaidzo; R S Heyderman; J Mielke; E Mushangi; A Taziwa; V J Robertson; P Musvaire; P R Mason
Journal:  AIDS       Date:  2000-07-07       Impact factor: 4.177

2.  Neuro-ophthalmological disorders in HIV infected subjects with neurological manifestations.

Authors:  J-C Mwanza; L K Nyamabo; T Tylleskär; G T Plant
Journal:  Br J Ophthalmol       Date:  2004-11       Impact factor: 4.638

3.  Free fluconazole for cryptococcal meningitis: too little of a good thing?

Authors:  Richard J Hamill
Journal:  Clin Infect Dis       Date:  2006-09-07       Impact factor: 9.079

4.  Practice guidelines for the management of cryptococcal disease. Infectious Diseases Society of America.

Authors:  M S Saag; R J Graybill; R A Larsen; P G Pappas; J R Perfect; W G Powderly; J D Sobel; W E Dismukes
Journal:  Clin Infect Dis       Date:  2000-04-20       Impact factor: 9.079

5.  Clinical presentation, natural history, and cumulative death rates of 230 adults with primary cryptococcal meningitis in Zambian AIDS patients treated under local conditions.

Authors:  P Mwaba; J Mwansa; C Chintu; J Pobee; M Scarborough; S Portsmouth; A Zumla
Journal:  Postgrad Med J       Date:  2001-12       Impact factor: 2.401

6.  Antifungal drug susceptibility of Cryptococcus neoformans from clinical sources in Nairobi, Kenya.

Authors:  Christine C Bii; Koichi Makimura; Shigeru Abe; Haruhiko Taguchi; Olga M Mugasia; Gutura Revathi; Njeri C Wamae; Shigeru Kamiya
Journal:  Mycoses       Date:  2007-01       Impact factor: 4.377

7.  AIDS-associated cryptococcal meningitis in Rwanda (1983-1992): epidemiologic and diagnostic features.

Authors:  J Bogaerts; D Rouvroy; H Taelman; A Kagame; M A Aziz; D Swinne; J Verhaegen
Journal:  J Infect       Date:  1999-07       Impact factor: 6.072

8.  Cryptococcal meningitis in human immunodeficiency virus-infected patients in Harare, Zimbabwe.

Authors:  R S Heyderman; I T Gangaidzo; J G Hakim; J Mielke; A Taziwa; P Musvaire; V J Robertson; P R Mason
Journal:  Clin Infect Dis       Date:  1998-02       Impact factor: 9.079

9.  Population-based surveillance for cryptococcosis in an antiretroviral-naive South African province with a high HIV seroprevalence.

Authors:  Kerrigan M McCarthy; Juliette Morgan; Kathleen A Wannemuehler; Sara A Mirza; Susan M Gould; Ntombi Mhlongo; Portia Moeng; Bonnie R Maloba; Heather H Crewe-Brown; Mary E Brandt; Rana A Hajjeh
Journal:  AIDS       Date:  2006-11-14       Impact factor: 4.177

10.  In vitro comparative efficacy of voriconazole and itraconazole against fluconazole-susceptible and -resistant Cryptococcus neoformans isolates.

Authors:  M H Nguyen; C Y Yu
Journal:  Antimicrob Agents Chemother       Date:  1998-02       Impact factor: 5.191

View more
  11 in total

1.  Clinical epidemiology and high genetic diversity amongst Cryptococcus spp. isolates infecting people living with HIV in Kinshasa, Democratic Republic of Congo.

Authors:  Bive Zono Bive; Rosalie Sacheli; Hippolyte Situakibanza Nani-Tuma; Pius Kabututu Zakayi; Alex Ka; Marcel Mbula Mambimbi; Gaultier Muendele; Raphael Boreux; Nicole Landu; Celestin Nzanzu Mudogo; Pierre-Robert M'Buze; Michel Moutschen; Wieland Meyer; Georges Mvumbi Lelo; Marie-Pierre Hayette
Journal:  PLoS One       Date:  2022-05-19       Impact factor: 3.752

2.  Troponoids Can Inhibit Growth of the Human Fungal Pathogen Cryptococcus neoformans.

Authors:  Maureen J Donlin; Anthony Zunica; Ashlyn Lipnicky; Aswin K Garimallaprabhakaran; Alex J Berkowitz; Alexandre Grigoryan; Marvin J Meyers; John E Tavis; Ryan P Murelli
Journal:  Antimicrob Agents Chemother       Date:  2017-03-24       Impact factor: 5.191

3.  Discovery of 5-Nitro-6-thiocyanatopyrimidines as Inhibitors of Cryptococcus neoformans and Cryptococcus gattii.

Authors:  Maureen J Donlin; Thomas R Lane; Olga Riabova; Alexander Lepioshkin; Evan Xu; Jeffrey Lin; Vadim Makarov; Sean Ekins
Journal:  ACS Med Chem Lett       Date:  2021-04-07       Impact factor: 4.345

Review 4.  Preventing Cryptococcosis-Shifting the Paradigm in the Era of Highly Active Antiretroviral Therapy.

Authors:  David Meya; Radha Rajasingham; Elizabeth Nalintya; Mark Tenforde; Joseph N Jarvis
Journal:  Curr Trop Med Rep       Date:  2015

5.  Cross talk between the cell wall integrity and cyclic AMP/protein kinase A pathways in Cryptococcus neoformans.

Authors:  Maureen J Donlin; Rajendra Upadhya; Kimberly J Gerik; Woei Lam; Laura G VanArendonk; Charles A Specht; Neil K Sharma; Jennifer K Lodge
Journal:  mBio       Date:  2014-08-12       Impact factor: 7.867

6.  Pd@Ag Nanosheets in Combination with Amphotericin B Exert a Potent Anti-Cryptococcal Fungicidal Effect.

Authors:  Chao Zhang; Mei Chen; Guizhen Wang; Wei Fang; Chen Ye; Hanhua Hu; Zhenzong Fa; Jiu Yi; Wan-Qing Liao
Journal:  PLoS One       Date:  2016-06-07       Impact factor: 3.240

Review 7.  Neurological disorders in HIV in Africa: a review.

Authors:  William P Howlett
Journal:  Afr Health Sci       Date:  2019-06       Impact factor: 0.927

8.  Prevalence of Cryptococcal Antigenemia and associated factors among HIV/AIDS patients on second-line antiretroviral therapy at two hospitals in Western Oromia, Ethiopia.

Authors:  Nuguse Geda; Tafese Beyene; Regea Dabsu; Hylemariam Mihiretie Mengist
Journal:  PLoS One       Date:  2019-12-05       Impact factor: 3.240

9.  Point of care testing evaluation of lateral flow immunoassay for diagnosis of cryptococcus meningitis in HIV-positive patients at an urban hospital in Nairobi, Kenya, 2017.

Authors:  Lawrence Kirimi Gitonga; Waqo Gufu Boru; Arthur Kwena; Marybeth Maritim; Joyce Wamicwe; James Ransom
Journal:  BMC Res Notes       Date:  2019-12-05

10.  Synthetic Derivatives of Ciclopirox are Effective Inhibitors of Cryptococcus neoformans.

Authors:  Jeffrey Lin; Maryam Zangi; Tanguturi Venkata Narayana Hajay Kumar; Makala Shakar Reddy; Lingala Vijaya Raghava Reddy; Subir Kumar Sadhukhan; Daniel P Bradley; Brenda Moreira-Walsh; Tiffany C Edwards; Austin T O'Dea; John E Tavis; Marvin J Meyers; Maureen J Donlin
Journal:  ACS Omega       Date:  2021-03-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.